U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Familial prostate carcinoma

MedGen UID:
419810
Concept ID:
C2931456
Neoplastic Process
Synonyms: Familial prostate cancer; Hereditary prostate cancer
SNOMED CT: Familial malignant neoplasm of prostate (715412008); Familial prostate cancer (715412008)
Modes of inheritance:
Not genetically inherited
MedGen UID:
988794
Concept ID:
CN307044
Finding
Source: Orphanet
clinical entity without genetic inheritance.
 
Monarch Initiative: MONDO:0023122
Orphanet: ORPHA1331

Definition

A small percentage of prostate cancers are hereditary and occur in families. These hereditary cancers are associated with inherited gene variants. Hereditary prostate cancers tend to develop earlier in life than non-inherited (sporadic) cases.

Some cancerous tumors can invade surrounding tissue and spread to other parts of the body. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers. The signs and symptoms of metastatic cancer depend on where the disease has spread. If prostate cancer spreads, cancerous cells most often appear in the lymph nodes, bones, lungs, liver, or brain.

The severity and outcome of prostate cancer varies widely. Early-stage prostate cancer can usually be treated successfully, and some older men have prostate tumors that grow so slowly that they may never cause health problems during their lifetime, even without treatment. In other men, however, the cancer is much more aggressive; in these cases, prostate cancer can be life-threatening.

Early prostate cancer usually does not cause pain, and most affected men exhibit no noticeable symptoms. Men are often diagnosed as the result of health screenings, such as a blood test for a substance called prostate specific antigen (PSA) or a medical exam called a digital rectal exam (DRE). As the tumor grows larger, signs and symptoms can include difficulty starting or stopping the flow of urine, a feeling of not being able to empty the bladder completely, blood in the urine or semen, or pain with ejaculation. However, these changes can also occur with many other genitourinary conditions. Having one or more of these symptoms does not necessarily mean that a man has prostate cancer.

Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal, multiply without control or order, and form a tumor. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm. [from MedlinePlus Genetics]

Professional guidelines

PubMed

de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R
Prostate 2024 Apr;84(5):426-440. Epub 2024 Jan 3 doi: 10.1002/pros.24664. PMID: 38173302
Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML; CGC, Karlan BY, Khan S, Klein C, Kohlmann W; CGC, Kurian AW, Laronga C, Litton JK, Mak JS; LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G; CGC, Senter-Jamieson L; CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA
J Natl Compr Canc Netw 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001. PMID: 33406487
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A
J Natl Compr Canc Netw 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011. PMID: 32135513

Curated

NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, Version 4.2022

UK NICE Guideline NG131, Prostate cancer: diagnosis and management, 2021

Suggested Reading

Recent clinical studies

Etiology

Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, Nishii M, Ohtake N, Nakata S, Ito K, Yamanaka H
Cancer 2003 Oct 1;98(7):1411-6. doi: 10.1002/cncr.11639. PMID: 14508827
Hemminki K, Czene K
Cancer 2002 Sep 15;95(6):1346-53. doi: 10.1002/cncr.10819. PMID: 12216104
Grönberg H, Wiklund F, Damber JE
Cancer 1999 Aug 1;86(3):477-83. PMID: 10430256

Diagnosis

Hemminki K, Czene K
Cancer 2002 Sep 15;95(6):1346-53. doi: 10.1002/cncr.10819. PMID: 12216104
Grönberg H, Wiklund F, Damber JE
Cancer 1999 Aug 1;86(3):477-83. PMID: 10430256

Prognosis

Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, Nishii M, Ohtake N, Nakata S, Ito K, Yamanaka H
Cancer 2003 Oct 1;98(7):1411-6. doi: 10.1002/cncr.11639. PMID: 14508827

Clinical prediction guides

Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, Nishii M, Ohtake N, Nakata S, Ito K, Yamanaka H
Cancer 2003 Oct 1;98(7):1411-6. doi: 10.1002/cncr.11639. PMID: 14508827

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • NCCN, 2022
      NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, Version 4.2022
    • NICE, 2021
      UK NICE Guideline NG131, Prostate cancer: diagnosis and management, 2021

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...